During COVID-19, researchers found that low-dose buprenorphine initiation for fentanyl users was largely unsuccessful, with ...

Members of the Sackler family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion to settle lawsuits over the toll of the powerful prescription painkiller.

Under a new state pilot, paramedics in Kitsap County will start administering a medication that blunts withdrawals and ...

If you have recently visited your doctor for pain management and were surprised when they did not prescribe opioids, you are ...

App users also stayed with their opioid agonist therapy an average 290 days, compared with 236 days for those who only got medication, the study says. “These results are promising, and they highlight ...

App users also stayed with their opioid agonist therapy an average 290 days, compared with 236 days for those who only got medication, the study says. “These results are promising, and they ...

"Our findings suggest that the mental health benefits of psilocybin therapy for cancer patients ... may also occur in psilocybin trials for opioid-use disorder. Bogenschutz cautions that in ...

Therapy through a smartphone app can help people reduce their opioid use and stay in treatment, according to a study from UT Health San Antonio. The study followed 600 adult patients with ...

Medetomidine is a non-opioid veterinary anesthetic drug and a synthetic alpha-2-adrenoceptor agonist that is not approved for human use. Increasingly, it’s being used with illicitly manufactured ...

Patients with opioid use disorder can reduce their days of opioid use and stay in treatment longer when using a smartphone app as supportive therapy in combination with medication, a new study by ...

known as opioid agonist treatment. (It uses medications such as buprenorphine, methadone and Suboxone to treat drug addiction.) “Diversion didn’t start with the introduction of prescribed ...